Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Non-Current Assets came in at $14.1 billion in Q1 2026, up 22.29% year-on-year from $11.5 billion in Q1 2025, and down 1.83% quarter-over-quarter from $14.4 billion in Q4 2025.
Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $14.1 billion for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $14.1 billion, up 22.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 billion (up 22.29% YoY), and the FY2025 annual result was $14.4 billion, up 25.88% from the prior year.
- Other Non-Current Assets came in at $14.1 billion for Q1 2026 at Johnson & Johnson, down from $14.4 billion in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $27.2 billion in Q1 2023 to a low of $7.7 billion in Q2 2023.
- The 5-year median for Other Non-Current Assets is $11.4 billion (2024), against an average of $12.3 billion.
- Peak annual rise in Other Non-Current Assets reached 166.61% in 2023, while the deepest fall reached 48.04% in 2023.
- Johnson & Johnson's Other Non-Current Assets stood at $8.6 billion in 2022, then surged by 64.09% to $14.2 billion in 2023, then fell by 19.35% to $11.4 billion in 2024, then grew by 25.88% to $14.4 billion in 2025, then fell by 1.83% to $14.1 billion in 2026.
- The last three Other Non-Current Assets figures came in at $14.1 billion (Q1 2026), $14.4 billion (Q4 2025), and $12.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | 200.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 14.11 Bn |
| Dec 28, 2025 | 14.37 Bn |
| Sep 28, 2025 | 12.42 Bn |
| Jun 29, 2025 | 12.19 Bn |
| Mar 30, 2025 | 11.53 Bn |
| Dec 29, 2024 | 11.41 Bn |
| Sep 29, 2024 | 10.92 Bn |
| Jun 30, 2024 | 10.54 Bn |
| Mar 31, 2024 | 14.13 Bn |
| Dec 31, 2023 | 14.15 Bn |
| Jul 2, 2023 | 10.08 Bn |
| Apr 2, 2023 | 7.70 Bn |
| Jan 1, 2023 | 27.24 Bn |
| Oct 2, 2022 | 8.63 Bn |
| Jul 3, 2022 | 9.44 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 6.87 Bn |
| Jul 4, 2021 | 7.17 Bn |
| Apr 4, 2021 | 6.54 Bn |